The Conversation (0)
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular GLUE degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:
- Morgan Stanley 23 rd Annual Global Healthcare Conference (New York, NY) – September 8, 2025.
- Stifel 2025 Virtual Immunology and Inflammation Forum – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 15, 2025, at 9:00 a.m. ET.
A webcast of the fireside chat will be accessible via the "Events & Presentations" section of Monte Rosa's website at ir.monterosatx.com , and an archived version will be made available for 30 days following the presentation.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa's QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry's leading pipeline of MGDs, which spans autoimmune and inflammatory diseases, oncology, and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com .
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
